Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

  1. Bertolotto, A.
  2. Arroyo, R.
  3. Celius, E.G.
  4. Comi, G.
  5. Havrdova, E.K.
  6. Honeycutt, W.D.
  7. Hunter, S.F.
  8. Izquierdo, G.
  9. Kornek, B.
  10. Miller, T.
  11. Mitsikostas, D.D.
  12. Singer, B.A.
  13. Ziemssen, T.
  14. Chung, L.
  15. Daizadeh, N.
  16. Afsar, S.
  17. Hashemi, L.
  18. Senior, P.
Revista:
Neurology and Therapy

ISSN: 2193-6536,  2193-8253

Any de publicació: 2020

Volum: 9

Número: 2

Pàgines: 443-457

Tipus: Article

DOI: 10.1007/S40120-020-00191-7 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus